Literature DB >> 11358896

Methotrexate in Crohn's disease.

D S Rampton1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11358896      PMCID： PMC1728338          DOI： 10.1136/gut.48.6.790

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  13 in total

1.  Methotrexate in Crohn's disease: results of a randomized, double-blind, placebo-controlled trial.

Authors:  S Arora; W Katkov; J Cooley; J A Kemp; D E Johnston; R H Schapiro; D Podolsky
Journal:  Hepatogastroenterology       Date:  1999 May-Jun

2.  A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators.

Authors:  B G Feagan; R N Fedorak; E J Irvine; G Wild; L Sutherland; A H Steinhart; G R Greenberg; J Koval; C J Wong; M Hopkins; S B Hanauer; J W McDonald
Journal:  N Engl J Med       Date:  2000-06-01       Impact factor: 91.245

3.  A randomized dose-response and pharmacokinetic study of methotrexate for refractory inflammatory Crohn's disease and ulcerative colitis.

Authors:  L J Egan; W J Sandborn; W J Tremaine; J A Leighton; D C Mays; M G Pike; A R Zinsmeister; J J Lipsky
Journal:  Aliment Pharmacol Ther       Date:  1999-12       Impact factor: 8.171

4.  Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

Authors:  R Maini; E W St Clair; F Breedveld; D Furst; J Kalden; M Weisman; J Smolen; P Emery; G Harriman; M Feldmann; P Lipsky
Journal:  Lancet       Date:  1999-12-04       Impact factor: 79.321

5.  Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial.

Authors:  R Oren; M Moshkowitz; S Odes; S Becker; D Keter; I Pomeranz; H Shirin; C Shirin; I Reisfeld; E Broide; A Lavy; A Fich; R Eliakim; J Patz; Y Villa; N Arber; T Gilat
Journal:  Am J Gastroenterol       Date:  1997-12       Impact factor: 10.864

6.  Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis.

Authors:  R F Willkens; H J Williams; J R Ward; M J Egger; J C Reading; P J Clements; E S Cathcart; C O Samuelson; M A Solsky; S B Kaplan
Journal:  Arthritis Rheum       Date:  1984-04

Review 7.  Does methotrexate increase the risk of infection or malignancy?

Authors:  K S Kanik; J M Cash
Journal:  Rheum Dis Clin North Am       Date:  1997-11       Impact factor: 2.670

8.  Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology.

Authors:  J M Kremer; G S Alarcón; R W Lightfoot; R F Willkens; D E Furst; H J Williams; P B Dent; M E Weinblatt
Journal:  Arthritis Rheum       Date:  1994-03

9.  Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators.

Authors:  B G Feagan; J Rochon; R N Fedorak; E J Irvine; G Wild; L Sutherland; A H Steinhart; G R Greenberg; R Gillies; M Hopkins
Journal:  N Engl J Med       Date:  1995-02-02       Impact factor: 91.245

10.  Efficacy of low-dose methotrexate in rheumatoid arthritis.

Authors:  M E Weinblatt; J S Coblyn; D A Fox; P A Fraser; D E Holdsworth; D N Glass; D E Trentham
Journal:  N Engl J Med       Date:  1985-03-28       Impact factor: 91.245
View more
  10 in total

Review 1.  Methotrexate for maintenance of remission in Crohn's disease.

Authors:  Vishal Patel; Yongjun Wang; John K MacDonald; John W D McDonald; Nilesh Chande
Journal:  Cochrane Database Syst Rev       Date:  2014-08-26

Review 2.  Gastrointestinal diseases and their oro-dental manifestations: Part 1: Crohn's disease.

Authors:  C X W Tan; H S Brand; N K H de Boer; T Forouzanfar
Journal:  Br Dent J       Date:  2016-12-16       Impact factor: 1.626

Review 3.  Understanding the Cautions and Contraindications of Immunomodulator and Biologic Therapies for Use in Inflammatory Bowel Disease.

Authors:  H Matthew Cohn; Maneesh Dave; Edward V Loftus
Journal:  Inflamm Bowel Dis       Date:  2017-08       Impact factor: 5.325

Review 4.  Anaemia in inflammatory bowel disease.

Authors:  Martyn Dibb; Sreedhar Subramanian
Journal:  Frontline Gastroenterol       Date:  2014-01-03

Review 5.  Low dosages: new chemotherapeutic weapons on the battlefield of immune-related disease.

Authors:  Jing Liu; Jie Zhao; Liang Hu; Yuchun Cao; Bo Huang
Journal:  Cell Mol Immunol       Date:  2011-03-21       Impact factor: 11.530

Review 6.  Maintenance of remission in Crohn's disease: current and emerging therapeutic options.

Authors:  Matthew J Brookes; Jonathon R B Green
Journal:  Drugs       Date:  2004       Impact factor: 9.546

7.  Methotrexate for the treatment of thyroid eye disease.

Authors:  Diego Strianese; Adriana Iuliano; Mariantonia Ferrara; Chiara Comune; Immacolata Baronissi; Pasquale Napolitano; Alessia D'Alessandro; Piergiacomo Grassi; Giulio Bonavolontà; Paola Bonavolontà; Antonio Sinisi; Fausto Tranfa
Journal:  J Ophthalmol       Date:  2014-01-08       Impact factor: 1.909

Review 8.  Medical Management of Crohn's Disease.

Authors:  Ajay K Gade; Nathan T Douthit; Erin Townsley
Journal:  Cureus       Date:  2020-05-29

9.  Potential Role of Methotrexate Polyglutamates in Therapeutic Drug Monitoring for Pediatric Inflammatory Bowel Disease.

Authors:  Ryan Morrow; Ryan Funk; Mara Becker; Ashley Sherman; Leon Van Haandel; Taina Hudson; Rebecca Casini; Valentina Shakhnovich
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-14

Review 10.  Optimal management of steroid-dependent ulcerative colitis.

Authors:  Hafiz M Waqas Khan; Faisal Mehmood; Nabeel Khan
Journal:  Clin Exp Gastroenterol       Date:  2015-11-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.